MaxCyte (NASDAQ:MXCT) Stock: Insider Maher Masoud Acquires 100,000 Shares

MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) CEO Maher Masoud bought 100,000 shares of the stock in a transaction on Tuesday, November 17th. The stock was bought at an average price of $1.21 per share, for a total transaction of $121,000.00. Following the completion of the purchase, the chief executive officer directly owned 575,000 shares in the company, valued at approximately $695,750. The trade was a 21.05% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

MaxCyte Stock Performance

Shares of MaxCyte stock opened at $1.29 on Friday. MaxCyte, Inc. has a one year low of $0.64 and a one year high of $1.80. The firm has a fifty day moving average of $1.25 and a two-hundred day moving average of $1.08.

MaxCyte (NASDAQ:MXCT – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.39 million. MaxCyte had a negative return on equity of 15.05% and a negative net margin of 81.40%. On average, equities research analysts forecast that MaxCyte, Inc. will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MaxCyte

Institutional investors have recently made changes to their positions in the stock. Vitruvian Partners LLP purchased a new stake in shares of MaxCyte in the second quarter valued at $6,203,328. Liontrust Investment Partners LLP acquired a new stake in shares of MaxCyte during the third quarter valued at $5,421,000. BlackRock Inc. purchased a new stake in MaxCyte during the 2nd quarter worth about $3,765,000. Brooklands Fund Management Ltd purchased a new stake in MaxCyte during the 1st quarter worth about $1,538,000. Finally, Renaissance Technologies LLC raised its stake in MaxCyte by 153.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,993,200 shares of the company’s stock valued at $1,400,000 after purchasing an additional 1,206,300 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MXCT has been the subject of several research analyst reports. Weiss Ratings cut MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. BTIG Research restated a “neutral” rating on shares of MaxCyte in a research report on Monday, August 24th. Finally, Stifel Nicolaus set a $4.00 price target on shares of MaxCyte in a research note on Thursday, November 12th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.50.

Check Out Our Latest Stock Analysis on MaxCyte

About MaxCyte

(Get Free Report)

MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.

Featured Articles

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.